Trial Condition(s):

Hepatocellular carcinoma, Treatment of advanced renal cell carcinoma

BAY43-9006/sorafenib+gem+cisplatin Phase I combination study

Bayer Identifier:

12386

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2006-003530-14

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

Trial Dates

November2006

March2008

Phase

Could I receive a placebo?

Products

Nexavar (Sorafenib, BAY43-9006)

Accepts Healthy Volunteers

N/A

Where to Participate

Locations

Status

Locations	Status
Locations Marienhospital Herne Universitätsklinik Herne, Germany, 44625	Status Completed		Contact Us: E-mail: [email protected] Phone: Not Available

Locations

Status

Locations

Marienhospital Herne Universitätsklinik

Herne, Germany, 44625

Status

Completed

Contact Us:

E-mail: [email protected]

Phone: Not Available

Hepatocellular carcinoma, Treatment of advanced renal cell carcinoma

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

Trial Purpose

Key Participation Requirements

sex

age

44 Years

76 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information